“For the first time we’re able to objectively quantify eye disease and very precisely monitor for even the most subtle of changes that even the Human Eye can’t see,” exclaims Dr. Sunil Malkani, a Vitreo-Retinal specialist. “Moreover, we’re incredibly excited about the applications this affords not only with Macular Degeneration but also with other retinal diseases including cancerous eye lesions. The earlier we can diagnose these diseases, the better we can treat and ultimately save vision or even lives.”“We are very excited that with thousands of attendees scheduled for this optometric convention, this will provide an ideal platform to launch our ground-breaking vision-saving technology,” exclaims Howard Loff, MD. “With a sensitivity of greater than 95% accuracy in assisting with the diagnosis of AMD, Retinalyze has the ability to create a new standard of care for eye diseases and in the very near future could be used by the vast majority of eye doctors. The initial pricing structure will include a continuing monthly participation fee of $25 per doctor and a $15 per patient fee for each Retinalyze scan. I not only see this as being a primary tool used by the more than 60,000 eye doctors here in the US but also by those around the world.” Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corp, stated, “We are very proud of the work of Health Discovery Corporation’s SVM image analysis expert Dr. Hong Zhang and his use of HDC’s patented Support Vector Machine Technology in the development of Retinalyze Analytics.” Dr. Barnhill continued, “As a 50% joint venture owner in Retinalyze, LLC, HDC could recognize significant revenue in the very near term as a result of the potential success of Retinalyze Analytics in the Ophthalmic arena.” Physicians interested in learning about Retinalyze Analytics’ referral and reimbursement program may contact Howard Loff, MD at email@example.com. To contact Health Discovery Corp, please send inquiries to firstname.lastname@example.org. About Doctors Optimal Formula LLC Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well-being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit www.DoctorsOptimalFormula.com. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.